Browse medicines

Use listed on the medicine record

Rheumatoid arthritis and other long-term inflammatory diseases

Use listed on the medicine record

Many advanced cancers, by releasing the immune brake on tumour-fighting T cells

Use listed on the medicine record

Psoriasis, psoriatic arthritis and inflammatory spine disease

Use listed on the medicine record

Early Alzheimer disease, confirmed by an amyloid scan or spinal fluid test

Use listed on the medicine record

High cholesterol after a heart attack, when statins are not enough

Use listed on the medicine record

A monthly infusion for early Alzheimer's disease, approved on a brain-scan measurement rather than on symptoms

Use listed on the medicine record

Eczema, asthma and other diseases driven by the same allergic pathway

Use listed on the medicine record

Very high cholesterol that statins alone cannot bring down far enough

Use listed on the medicine record

Lymphomas and autoimmune diseases driven by B cells

Use listed on the medicine record

Breast and stomach cancers driven by an over-copied growth receptor

Use listed on the medicine record

Psoriasis, psoriatic arthritis and inflammatory bowel disease

Use listed on the medicine record

Advanced cancers, by restoring exhausted immune cells

Use listed on the medicine record

Several advanced cancers, by cutting off the blood supply a tumour builds for itself

Use listed on the medicine record

Stopping the microscopic clots of acquired TTP by cutting the tether that platelets are being dragged onto

Use listed on the medicine record

A subcutaneous injection, given as rarely as monthly, that stops the joint and muscle bleeds of haemophilia A without replacing the missing clotting factor

Use listed on the medicine record

Early Alzheimer disease, with treatment stopped once the plaque is cleared

Use listed on the medicine record

A weekly injection for severe plaque psoriasis

Use listed on the medicine record

Switching off the blood thinner dabigatran in an emergency — a serious bleed, or an operation that cannot wait

Use listed on the medicine record

Leaking abnormal blood vessels growing under the centre of the retina

Use listed on the medicine record

Severe bone thinning in women at high risk of breaking a bone, treated for one year only

Use listed on the medicine record

A monthly infusion for relapsing multiple sclerosis, given under a mandatory monitoring programme

Use listed on the medicine record

LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated: Cutaneous Squamous Cell Carcinoma (CSCC) for the treatment of adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. ( 1.1 ) for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation.

Use listed on the medicine record

Moderate to severe plaque psoriasis

Use listed on the medicine record

Recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy ( 1

Use listed on the medicine record

Adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC) [see Clinical Studies (14

Use listed on the medicine record

The following autoinflammatory Periodic Fever Syndromes

Use listed on the medicine record

Postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors fo

Use listed on the medicine record

High-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy

Use listed on the medicine record

Primary advanced or recurrent endometrial cancer

Use listed on the medicine record

Resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor

Use listed on the medicine record

Allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods

Use listed on the medicine record

Severe asthma aged 18 years and older with an eosinophilic phenotype

Use listed on the medicine record

Moderate-to-severe plaque psoriasis

Use listed on the medicine record

Multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative

Use listed on the medicine record

Metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy

Use listed on the medicine record

Acute organ rejection

Use listed on the medicine record

Eosinophilic granulomatosis with polyangiitis

Use listed on the medicine record

Moderate to severe plaque psoriasis

Use listed on the medicine record

Moderately to severely active rheumatoid arthritis

Use listed on the medicine record

TREMFYA is an interleukin-23 antagonist indicated for the treatment of: adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with moderate-to-severe plaque psoriasis and who are candidates for systemic therapy or phototherapy. ( 1.1 ) adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with active psoriatic arthritis. ( 1.2 ) adults with moderately to severely active ulcerative colitis. ( 1.3 ) adults with moderately to severely active Crohn's disease.

Use listed on the medicine record

Patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

Use listed on the medicine record

Severe asthma with an eosinophilic phenotype

Use listed on the medicine record

OCREVUS is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults Relapsing-remitting MS, in pediatric patients 10 years of age and older who weigh 25 kg or more.

Use listed on the medicine record

KEVZARA ® is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). ( 1.1 ) adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. ( 1.2 ) patients who weigh 63 kg or greater with active polyarticular juvenile idiopathic arthritis (pJIA).

Use listed on the medicine record

Generalized pustular psoriasis

Use listed on the medicine record

Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration

Use listed on the medicine record

Moderate-to-severe plaque psoriasis in aduts who are candidates for systemic therapy or phototherapy

Use listed on the medicine record

Moderate-to-severe atopic dermatitis

Use listed on the medicine record

REMICADE is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease.

Use listed on the medicine record

TOFIDENCE ® (tocilizumab-bavi) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.3 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis.

Use listed on the medicine record

ENTYVIO is indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). moderately to severely active Crohn's disease (CD). ENTYVIO is an integrin receptor antagonist indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). ( 1 ) moderately to severely active Crohn's disease (CD). ( 1 )

Use listed on the medicine record

Relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease

Use listed on the medicine record

Locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease

Use listed on the medicine record

Moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy

Use listed on the medicine record

Recurrence of Clostridioides difficile infection

Use listed on the medicine record

BEOVU ® is indicated for the treatment of: BEOVU is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Diabetic Macular Edema (DME) ( 1.2 ) 1.1 Neovascular (Wet) Age-related Macular Degeneration (AMD) 1.2 Diabetic Macular Edema (DME)

Use listed on the medicine record

Metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy

Use listed on the medicine record

RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season

Use listed on the medicine record

The treatment of adult patients with multiple myeloma

Use listed on the medicine record

The preventive treatment of migraine